Analysts suggest investing in HDFC Bank, Wockhardt, ACME Solar, Titagarh Rail, and Bajaj Finance for potential growth. Predicted price targets are Rs 796 for HDFC Bank, Rs 870 for Titagarh Rail, Rs 320 for ACME Solar, Rs 1,700 for Wockhardt, and Rs 970 for Bajaj Finance.

The NSE BSE Healthcare Index monitors the performance of various healthcare-related businesses, such as pharmaceuticals and hospitals. Companies like Wockhardt are among those being tracked in this index. This provides a comprehensive overview of market trends within the healthcare sector. [economictimes.com]

ICRA has elevated Wockhardt's credit rating to A/Stable for term loans and fund-based limits due to enhanced financial performance, strong market standing, robust liquidity, and favorable capital structure.

Analyst Kunal Kamble suggests Tata Fertilizer (TFCILTD), HBL Engineering, and Wockhardt as promising investments for May 7. These selections are driven by positive indicators such as bullish trends, breakouts, and robust RSI levels, suggesting a potential continuation of an upward trend.

NK Securities sold approximately 1 million shares of Wockhardt Ltd., with an average selling price of around Rs 1,720 each on the National Stock Exchange.

The pharmaceutical index Nifty Pharma reached a 52-week peak today at 24,033.45, registering a 2% increase. Notably, Wockhardt saw a 15% surge. Other companies like Lupin, Laurus, and Sun Pharma also hit new highs. Ajanta Pharma is experiencing strong growth in its branded business segment.

Mid-sized companies like Wockhardt and Coforge have experienced a notable 14% surge, indicating a robust resurgence within the midcap market as reported by ETMarkets.

Valor Estate's share price has skyrocketed by 30% over three days, reaching Rs 135 on BSE, in response to a positive decision from the Bombay High Court in favor of the company.

Wockhardt reports a significant turnaround in Q4 profits, jumping from a loss of ₹45 crore last year to ₹164 crore this year. The company's revenue also grew by 30% to ₹965 crore. EBITDA increased substantially to ₹225 crore, and as a result, Wockhardt shares have seen a rise of 2.5%, currently trading at ₹1,431. Over the last month, their shares have gained 12%.

Wockhardt's Q4 profits saw a substantial 29.9% year-on-year increase, reflecting a strong revenue growth.

Wockhardt's Q4 earnings show a substantial improvement, with EBITDA increasing over four times year-on-year to reach ₹2.25 billion. The company also achieved a more significant margin of 23.3%, up from 8.6% in the same period last year.

CAMS and Wockhardt's shares surge due to impressive financial outcomes, attracting more investors. Vodafone Idea continues to gain ground for a second day following AGR updates, with optimistic discussions about potential investments.

Wockhardt reported a significant increase in revenue and net profit for the fiscal year ending March 2026, with revenues reaching INR 1739 crores and a net profit of INR 317 crores. The company has plans to raise funds through an equity securities offering, pending approval from shareholders.

Pharmaceutical company Wockhardt experienced an 8% surge in shares after posting strong Q4 results, while Tata Technologies saw a 5% increase in the same trading session.

In contrast to the broader market's decline due to increasing Iran-US tensions and a weakening rupee, stocks like Wockhardt and Tata Tech stood out with gains of up to 11%, indicating resilience among some smallcap companies.

Wockhardt Ltd continues its upward trend, increasing by 3.6% today, marking a five-day winning streak for the company.

Wockhardt's antibiotic Zaynich, demonstrating promising efficacy and safety in trials, secures a favorable recommendation from the CDSCO expert committee, bringing it closer to achieving final approval.